Regulatory T Cells in the Control of Autoimmunity: the  Essential Role of  Transforming Growth Factor β and  Interleukin 4 in the Prevention of Autoimmune  Thyroiditis in Rats by Peripheral CD4+CD45RC−  Cells and CD4+CD8− Thymocytes by Seddon, Benedict & Mason, Don
 
279
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/99/01/279/10 $2.00
Volume 189, Number 2, January 18, 1999 279–288
http://www.jem.org
 
Regulatory T Cells in the Control of Autoimmunity: the 
Essential Role of Transforming Growth Factor 
 
b 
 
and 
Interleukin 4 in the Prevention of Autoimmune 
 
Thyroiditis in Rats by Peripheral CD4
 
1
 
CD45RC
 
2
 
 
Cells and CD4
 
1
 
CD8
 
2
 
 Thymocytes
 
By Benedict Seddon and Don Mason
 
From the Medical Research Council Cellular Immunology Unit, Sir William Dunn School of 
Pathology, University of Oxford, Oxford OX1 3RE, United Kingdom
 
Summary
 
Previous studies have shown that induction of autoimmune diabetes by adult thymectomy and
split dose irradiation of PVG.RT1
 
u
 
 rats can be prevented by their reconstitution with periph-
eral CD4
 
1
 
CD45RC
 
2
 
TCR-
 
a
 
/
 
b
 
1
 
RT6
 
1
 
 cells and CD4
 
1
 
CD8
 
2
 
 thymocytes from normal syn-
geneic donors. These data provide evidence for the role of regulatory T cells in the prevention
of a tissue-specific autoimmune disease but the mode of action of these cells has not been re-
ported previously. In this study, autoimmune thyroiditis was induced in PVG.RT1
 
c
 
 rats using a
similar protocol of thymectomy and irradiation. Although a cell-mediated mechanism has been
implicated in the pathogenesis of diabetes in PVG.RT1
 
u
 
 rats, development of thyroiditis is in-
dependent of CD8
 
1
 
 T cells and is characterized by high titers of immunoglobulin (Ig)G1 anti-
thyroglobulin antibodies, indicating a major humoral component in the pathogenesis of dis-
ease. As with autoimmune diabetes in PVG.RT1
 
u
 
 rats, development of thyroiditis was
prevented by the transfer of CD4
 
1
 
CD45RC
 
2
 
 and CD4
 
1
 
CD8
 
2
 
 thymocytes from normal do-
nors but not by CD4
 
1
 
CD45RC
 
1
 
 peripheral T cells. We now show that transforming growth
factor (TGF)-
 
b
 
 and interleukin (IL)-4 both play essential roles in the mechanism of this protec-
tion since administration of monoclonal antibodies that block the biological activity of either of
these cytokines abrogates the protective effect of the donor cells in the recipient rats. The pre-
vention of both diabetes and thyroiditis by CD4
 
1
 
CD45RC
 
2
 
 peripheral cells and CD4
 
1
 
CD8
 
2
 
thymocytes therefore does not support the view that the mechanism of regulation involves a
switch from a T helper cell type 1 (Th1) to a Th2-like response, but rather relies upon a spe-
cific suppression of the autoimmune responses involving TGF-
 
b
 
 and IL-4. The observation
that the same two cytokines were implicated in the protective mechanism, whether thy-
mocytes or peripheral cells were used to prevent autoimmunity, strongly suggests that the reg-
ulatory cells from both sources act in the same way and that the thymocytes are programmed in
the periphery for their protective role. The implications of this result with respect to immuno-
logical homeostasis are discussed. 
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R
 
ats and mice that are relatively T cell deficient for
genetic reasons, or that are made so experimentally,
develop a range of tissue-specific autoimmune diseases that
can be prevented by the transfer of the appropriate T cell
subset from syngeneic, nonlymphopenic donors. These
observations demonstrate that self-tolerance is an active
process and is not achieved entirely by a combination of
deletion of autoreactive T cells intrathymically and of
clonal anergy, deletion, or indifference in the periphery
(1–5). Studies in this laboratory have shown that insulin-
dependent diabetes is induced in a normal strain of labora-
tory rat by thymectomy at 6 wk of age followed by four
equal doses of 250-rad 
 
137
 
Cs 
 
g
 
-irradiation at 2-wk intervals.
Rats develop disease over the ensuing 10–12 wk, charac-
terized by infiltration of pancreatic islets and selective de-
struction of the 
 
b
 
 cells in virtually all males and 70% of fe-
males. Disease is prevented in 
 
z
 
50% of rats reconstituted
shortly after the last irradiation with peripheral CD4
 
1
 
 cells 
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from syngeneic donors. Phenotypic analysis of these cells
identified a subset of cells that protected 100% of recipients
from diabetes as being CD4
 
1
 
CD45RC
 
2
 
TCR-
 
a
 
/
 
b
 
1
 
RT6
 
1
 
(6). Some of the cells with this phenotype have been
shown to produce IL-4 on activation in vitro (7) and pro-
vide B cells with help for secondary antibody responses (8),
raising the possibility that the prevention of diabetes in-
volved a switch from a proinflammatory, cell-mediated,
Th1 response to a nonpathogenic humoral one. The pe-
ripheral T cells that prevented diabetes in these experi-
ments have a memory phenotype, suggesting that they are
primed in the periphery to some undefined antigen. How-
ever, when CD4
 
1
 
CD8
 
2
 
 thymocytes were assayed for their
ability to prevent diabetes in this system, it was found that
these were much more potent in regulating the disease than
were the peripheral memory cells (9). This unexpected
finding raised questions about the mechanisms of disease
prevention by the cells from the two sources and the devel-
opmental relationship between them. To examine these
questions, we have studied another lymphopenia-induced
autoimmune disease, which unlike the autoimmune diabe-
tes has a strong humoral component.
In studies that originally described the development of
autoimmunity in normal rats after thymectomy and irradia-
tion (TxX protocol), autoimmune thyroiditis, character-
ized by leukocytic infiltration of thyroid glands and the
development of high titers of antithyroglobulin (Tg)
 
1
 
 anti-
bodies, was induced in PVG.RT1
 
c
 
 strain rats (10, 11). In
these same studies it was shown that reconstitution of these
lymphopenic rats with splenocytes from normal syngeneic
recipients could prevent disease development. However,
the phenotype and function of the regulatory T cells that
prevent it has not been determined previously. In this study
we show that, although thyroiditis in such rats is character-
ized by a humoral, anti-Tg response, it is the CD4
 
1
 
CD45RC
 
2
 
 subset that is responsible for protection from
disease. As noted above, this same subset prevents the cell-
mediated diabetes observed in TxX PVG.RT1
 
u
 
 rats (6).
Further similarities in the mechanisms that prevent the two
diseases are shown by the observation that, as with the pre-
vention of diabetes, CD4
 
1
 
CD8
 
2
 
 thymocytes are also very
potent at preventing autoimmune thyroiditis. Finally, we
show that the cytokines IL-4 and TGF-
 
b
 
 both play an
essential role in the mechanism of protection by both pe-
ripheral CD4
 
1
 
CD45RC
 
2
 
 T cells and CD4
 
1
 
CD8
 
2
 
 thy-
mocytes, strongly suggesting that the same cellular mecha-
nism is involved.
 
Materials and Methods
 
Monoclonal Antibodies.
 
The mouse mAbs used in these studies
were as follows: W3/25 (anti–rat CD4; reference 12); OX6
(anti–rat class II MHC; reference 13); OX8 (anti–rat CD8; refer-
 
ence 14); OX12 (anti–rat 
 
k
 
 chain; reference 15); OX21 (anti–
human C3b inactivator, IgG1; reference 16); OX22 (anti–rat
exon C of CD45; references 8, 17); OX32 (anti–rat exon C of
CD45, non-competing with OX22; references 17, 18); OX81
(anti–rat IL-4, IgG1; reference 19), 2G.7 (anti–human TGF-
 
b
 
,
IgG2a; reference 20); and W6/32 (anti–human class I, IgG2a;
reference 21).
 
Animals and Induction of Thyroiditis.
 
3–12-wk-old female
PVG.RT1
 
c
 
 (PVG) rats were obtained from the specific patho-
gen–free breeding facilities of the Medical Research Council
Cellular Immunology Unit (Oxford, UK). Thyroiditis was in-
duced in female PVG rats as has been previously described (11).
In brief, 3-wk-old female rats were thymectomized and given
four 275-rad doses of 
 
137
 
Cs 
 
g
 
-irradiation at 2-wk intervals starting
1 wk after thymectomy (TxX). Development of thyroiditis was
determined histologically and by the development of anti-Tg an-
tibodies. Since the incidence of thyroiditis is higher in females
(
 
z
 
70%) than males (
 
z
 
50%), female rats were used exclusively for
thyroiditis induction.
 
Isolation of T Cell Subpopulations.
 
Rat thoracic duct lympho-
cytes (TDLs) were obtained by cannulation of the duct (22). Cells
were collected at 4
 
8
 
C overnight into flasks containing PBS and
20 U/ml heparin. Rat lymphocyte populations were negatively
selected from TDLs using a rosetting technique as described else-
where (23) or using magnetic beads (Dynal). CD4
 
1
 
 T cells were
isolated by depletion of B cells and CD8
 
1
 
 T cells using the mAbs
OX12, OX8, and OX6. To obtain CD4
 
1
 
CD45RC
 
2
 
 T cells,
TDLs were depleted using the mAbs OX22, OX32, and OX8.
CD4
 
1
 
CD8
 
2
 
 thymocytes were purified from thymus of 6-wk-old
PVG rats by depletion of CD8
 
1
 
 cells. The purity of all isolated
cells was analyzed on a FACScan
 
®
 
 (Becton Dickinson) by label-
ing pre- and postdepletion samples with rabbit anti–mouse FITC.
The percentage of contaminated cells was 
 
,
 
2%.
CD4
 
1
 
CD45RC
 
high
 
 cells were isolated by positive selection us-
ing MACS microbeads (Miltenyi Biotec). CD4
 
1
 
 T cells, purified
from TDLs by rosette depletion, were labeled with a limiting
concentration of OX32 tissue culture supernatant such that only
cells expressing the highest levels of CD45RC were labeled by
mAb. OX32-labeled cells were in turn labeled with goat anti–
mouse Ig microbeads (Miltenyi Biotec) and run down a positive
selection column. The purity of eluted CD45RC
 
high
 
 cells, as de-
termined by labeling a sample with saturating levels of OX22
mAb and RAM-FITC, was 
 
.
 
99.5%.
 
Detection and Quantitation of Anti-Tg Antibodies in Sera of Rats.
 
Sera from TxX rats were assayed every 2 wk for anti-Tg antibod-
ies between 4 and 12 wk after the last irradiation by specific
ELISA. 96-well microtiter plates were coated overnight with pu-
rified rat Tg (20 
 
m
 
g/ml) and blocked for 30 min with 1% BSA in
PBS. Sera of individual rats at four fivefold dilutions starting at 1:10
were incubated for 2 h at room temperature. Rat IgG was de-
tected using anti–rat IgG alkaline phosphatase conjugate (Sigma
Chemical Co.) for 1 h at room temperature, and different rat Ig
isotypes were detected using biotinylated mAbs (1 
 
m
 
g/ml) spe-
cific for IgG1 (PharMingen), IgG2a (Serotec Ltd.), and IgG2b
(PharMingen) for 1 h at room temperature followed by a 1 h in-
cubation with avidin alkaline phosphatase (Sigma Chemical Co.).
Plates were washed three times between each step with 0.05%
Tween 20/PBS. The assay was developed using enzyme substrate
4-nitro-phenyl phosphate (5 mg/ml; Sigma Chemical Co.) for 15
min at room temperature before reading the OD at 405 nm.
Anti-Tg antibody titers were quantified by comparison with a
standard serum pooled from TxX rats with thyroiditis and high
anti-Tg antibody titers and expressed as a percentage of this stan-
 
1
 
Abbreviations used in this paper:
 
 TDL, thoracic duct lymphocytes; Tg, thy-
roglobulin; NOD, nonobese diabetic; PVG, PVG.RT1
 
c
 
; T reg, regula-
tory T cells. 
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dard. The level of nonspecific binding found in normal PVG se-
rum represented a titer of 
 
z
 
0.1% in the assay, and therefore only
sera with titers 
 
.
 
0.3% were considered to contain specific anti-
Tg antibodies.
 
Histological Analysis.
 
Whole thyroids attached to cricoid car-
tilage were dissected out and fresh frozen in O.C.T. embedding
medium (Sakura Finetek U.S.A. Inc.). 10-
 
m
 
m sections were cut
from frozen blocks and stained with hematoxylin and eosin.
 
Statistical Analysis.
 
Incidence of thyroiditis development in
two different groups of TxX PVG rats was compared for statisti-
cally significant differences using Fisher’s exact test for consis-
tency in a 2 
 
3
 
 2 table.
 
Results
 
Development of Thyroiditis in TxX Rats Is Associated with a
Humoral Th2 Autoimmune Response.
 
Previous studies have
shown that normal rats with no tendency to spontaneously
develop autoimmunity will develop organ-specific autoim-
munity in a strain-dependent fashion if thymectomized and
given four equal doses of 
 
g
 
-irradiation at 2-wk intervals.
After thymectomy and irradiation, female PVG rats sponta-
neously develop autoimmune thyroiditis characterized by
extensive infiltration of thyroid glands and development of
high titers of anti-Tg antibodies (10, 11). In contrast, simi-
lar treatment of PVG.RT1
 
u
 
 strain rats, differing from PVG
rats only in their MHC haplotype, results in the develop-
ment of a fatal insulin-dependent diabetes 4–10 wk after
the last irradiation at a high incidence in males (6). Studies
of the pathogenesis of diabetes in both TxX PVG.RT1
 
u
 
rats and the nonobese diabetic (NOD) mouse strongly im-
plicate a Th1 cell–mediated mechanism, since CD8
 
1
 
 T
cells are required for disease development (6, 24) and ma-
nipulations that antagonize development of Th1 responses
protect NOD mice from disease development (25–27).
To further characterize the pathogenesis of thyroiditis
development in TxX PVG rats, the use of different IgG
isotypes in the anti-Tg antibody response was analyzed. In
the rat, antibodies of the IgG1 isotype, like those in the
mouse, are associated with a Th2 response, whereas IgG2b
isotype synthesis, in contrast to that in mice, is indicative of
a Th1 response. The IgG2a isotype is not preferentially fa-
vored by either Th1 or Th2 reactions (28, 29). Although
no anti-Tg IgG of any isotype was detectable in the sera of
normal rats (data not shown), sera of TxX rats with thy-
roiditis consistently contained high titers of anti-Tg IgG of
the IgG1 isotype, with little specific IgG2a or IgG2b anti-
bodies (Fig. 1 A). This profile of anti-Tg IgG isotype usage
contrasted significantly with that of normal PVG rats im-
munized with Tg in CFA, an adjuvant known to induce
Th1 responses. Normal 12-wk-old PVG rats immunized
with Tg (50 
 
m
 
g/rat) in CFA developed anti-Tg IgG of the
IgG2b isotype, with little anti-Tg IgG1 (Fig. 1 A).
Because the isotype of anti-Tg IgG antibodies in TxX
rats indicated that the pathogenesis involved the activity of
Th2 cells, the requirement for CD8
 
1
 
 T cells in the devel-
opment of thyroiditis was tested. PVG rats were depleted
of CD8
 
1
 
 
 
cells by injection, at the time of thymectomy and
 
1 wk after thymectomy, with purified depleting anti-CD8
mAb OX8 in PBS (0.5 mg/injection). Control rats re-
ceived injections of PBS alone. Although treated rats were
still depleted of TCR
 
1
 
 CD8
 
1
 
 cells 12 wk after their last ir-
radiation (data not shown), they developed thyroiditis at a
similar frequency to control rats (Fig. 1 B) (
 
P
 
 
 
.
 
 0.24). In
principle, it is possible that residual CD8
 
1
 
 cells, whose
presence was not readily detectable by FACS
 
®
 
 analysis, me-
diated disease development. However, it is notable that
similar depletion of CD8
 
1
 
 cells in PVG.RT1
 
u
 
 rats was suf-
ficient to completely prevent diabetes, suggesting that the
depletion regime was effective (6).
 
Reconstitution of TxX PVG Rats with Syngeneic CD4
 
1
 
CD45RC
 
2
 
 Cells Completely Prevents Thyroiditis.
 
In previ-
ous studies of autoimmunity in TxX rats, development of
diabetes could be prevented in 
 
z
 
50% of PVG.RT1
 
u
 
 rats by
their reconstitution with unfractionated CD4
 
1
 
 T cells from
normal syngeneic donors (6). Similarly, thyroiditis devel-
opment was prevented in TxX PVG rats by their reconsti-
tution with unfractionated splenocytes (30). In the former
case, protection from diabetes development was shown to
be mediated by the CD41CD45RC2 subset of CD41 T
cells and antagonized by the CD41CD45RC1 subset. This
antagonism explained why unfractionated CD41 T cells
protected only some recipients while, in contrast, all predi-
abetic rats given the CD41CD45RC2 subset were free of
disease. Cells that share this protective CD41CD45RC2
phenotype provide B cells with help for secondary anti-
Figure 1. Thyroiditis in PVG rats after their thymectomy and irradia-
tion develops independently of CD81 cells and is characterized by a Th2-
like anti-Tg IgG response. Female PVG rats were thymectomized at 3 wk
of age followed 1 wk later, by four doses of 275 rad 137Cs g-irradiation at
2-wk intervals. (A) The isotype of anti-Tg IgG antibodies in sera of TxX
rats with thyroiditis (n 5 25) and normal 12-wk-old female PVG rats im-
munized with Tg (50 mg/rat) in CFA (n 5 5) was determined by specific
ELISA. Data are expressed as the mean percentage of the anti-Tg re-
sponse for each IgG isotype where 100% is the sum of the ODs for indi-
vidual isotypes above background of normal PVG sera in 1:10 dilutions of
an experimental serum. Error bars indicate SD. (B) The requirement for
CD81 cells in the development of thyroiditis in TxX PVG rats was deter-
mined by their injection at the time of thymectomy and 7 d later with ei-
ther the anti-CD8-depleting mAb OX8 (0.5 mg/injection) or PBS as con-
trol. Development of anti-Tg IgG responses was monitored between 4 and
12 wk after the last irradiation by specific ELISA. Data represent peak anti-
Tg IgG titers expressed as percentage of standard for individual TxX rats.
FACS® analysis of splenocytes from OX8-treated rats, 12 wk after the last
irradiation, showed that ,2% of TCR1 cells were CD81 (data not
shown). Data are representative of two independent experiments.282 Immunoregulation of Autoimmunity Mediated by TGF-b and IL-4
body responses (28) and produce IL-4 after activation in
vitro (7) and therefore have some of the characteristics of
Th2 cells. In principle then, protection from diabetes could
have reflected a switch from a cell-mediated to a humoral
response toward islet cell autoantigens. In contrast to the
cell-mediated mechanisms implicated in the pathogenesis of
diabetes, the IgG isotypes of anti-Tg responses in rats with
thyroiditis indicate the activity of Th2 cells and this observa-
tion calls into question the possible involvement of a Th1 to
Th2 switch in preventing these autoimmune diseases. How-
ever, the preceding data did not exclude the possibility that
different subsets of CD41 T cells were involved in the pre-
vention of these two diseases. To examine this possibility, a
comparison was made of the abilities of CD41CD45RC2
and CD41CD45RC1 cells to prevent thyroiditis.
Consistent with previous studies (30), reconstitution of
TxX PVG rats with 107 unfractionated CD41 TDLs
shortly after their last irradiation prevented development of
thyroiditis in a high proportion of recipients (Fig. 2). Sig-
nificantly, however, TxX PVG rats reconstituted with 107
CD41CD45RC1 TDLs shortly after their final irradiation
developed thyroiditis at the same frequency as control rats
(Fig. 2). In contrast, TxX rats injected with 107 CD41
CD45RC2 TDLs shortly after their final irradiation were
completely protected from development of both serological
(Fig. 2) and histological (Fig. 3) signs of disease.
CD41CD82 Thymocytes Are a Potent Source of Cells that
Prevent Autoimmune Thyroiditis. Previous studies in this
laboratory showed that diabetes could be prevented in a
large proportion of TxX PVG.RT1u rats after their recon-
stitution with CD41CD82 thymocytes (6). Further experi-
ments indicated that these thymocytes were effective at
preventing diabetes at a significantly lower dose than re-
quired for peripheral CD41CD45RC2 T cells (9). To de-
termine whether CD41CD82 thymocytes were equally
potent at preventing thyroiditis they were tested for their
ability to control onset of this disease at different cell doses.
PVG rats, thymectomized at 3 wk of age and given four
doses of 275 rad g-irradiation, were reconstituted shortly
after their last irradiation either with purified CD41CD82
thymocytes at doses of 107, 5 3 106, 106, 5 3 105, or 105
per rat, or with CD41CD45RC2 cells purified from TDLs
of 12-wk-old normal donors at doses of 107, 5 3 106, or
Figure 2. Prevention of thyroiditis development in TxX PVG rats by
their reconstitution with either CD41CD45RC2 T cells or CD41CD82
thymocytes. Unfractionated CD41 and CD41CD45RC2 cells were puri-
fied from TDLs of 12-wk-old normal PVG rats by Dynal bead depletion.
CD41CD45RC1 cells were purified from CD41 TDLs by positive selec-
tion using MACS beads, whereas CD41CD82 thymocytes were purified
from thymus of 6-wk-old rats by depletion of CD81 cells as described in
Materials and Methods. Shortly after their last irradiation, TxX PVG rats
were reconstituted with 107 of unfractionated CD41 cells, CD41
CD45RC2 cells, CD41CD45RC1 cells, or CD41CD82 thymocytes,
while control rats received no cells. Data represent peak anti-Tg IgG anti-
body levels in individual TxX rats from groups reconstituted with differ-
ent T cell subsets. Anti-Tg titers are expressed as percentage of a standard
and data are the pool of six independent experiments. Statistics versus
controls:  aP , 1024; bP , 1.2 3 1028; cP . 0.52; dP , 3 3 1026.
Figure 3. Immunopathology of the thyroid glands from control TxX
rats and those reconstituted with CD41CD45RC2 T cells. In experi-
ments similar to those described in Fig. 2, thyroid glands were taken at
the time of peak disease, sectioned, and stained with hematoxylin and
eosin. Thyroids from control TxX PVG rats (A; original magnification
3200) show extensive mononuclear cell infiltrate and loss of follicular
structure. In contrast, thyroid glands from TxX PVG rats reconstituted
with 107 CD41CD45RC2 cells shortly after their last irradiation are of
normal morphology with no signs of infiltration (B; original magnifica-
tion 3200). Similarly, thyroids of TxX PVG rats protected by their re-
constitution with CD41CD82 thymocytes were of normal morphology
with no signs of infiltration (data not shown).283 Seddon and Mason
106 per rat. In agreement with studies of diabetes in
PVG.RT1u rats, most but not all rats reconstituted with 107
CD41CD82 thymocytes were protected from develop-
ment of thyroiditis (Fig. 2) and, significantly, these thy-
mocytes were found to be highly potent in controlling the
disease. An indistinguishable level of protection was ob-
served in recipients of a range of CD41CD82 thymocyte
doses, between 5 3 105 and 107 cells/rat. Only at doses be-
low 5 3 105 CD41CD82 thymocytes was protection lost
(Fig. 4). In contrast, although recipients of 107 CD41
CD45RC2 cells were protected from disease development,
a low incidence of disease was observed in recipients of half
that number of CD41CD45RC2 cells, and rats reconsti-
tuted with 106 CD41CD45RC2 cells were not protected
at all (Fig. 4).
Prevention of Thyroiditis by Peripheral or Thymic CD41 T
Cells Is Abrogated by Blockade of either TGF-b or IL-4 Activity.
Results from this present and previous studies (6) have
established that the regulatory subset of peripheral T
cells that prevent autoimmunity in TxX rats are CD41
CD45RC2RT61TCR-a/b1, and furthermore, that CD41
CD82 thymocytes are also a potent source of cells with a
similar regulatory capacity. However, the mechanisms by
which these different populations prevent autoimmunity
and whether the regulatory cells in the thymus and those in
the periphery represent the same lineage of cells has not
been examined until now. By using mAbs that specifically
block the biological activities of TGF-b and IL-4 it was
possible to determine the role of these cytokines in the
protection of rats from development of thyroiditis follow-
ing their reconstitution with either CD41CD45RC2 cells
or CD41CD82 thymocytes. Groups of PVG rats, thymec-
tomized neonatally and 1 wk later started on a regime of
four 275-rad doses of 137Cs g-irradiation at 2-wk intervals,
were reconstituted shortly after their last irradiation with
either 5 3 106 CD41CD45RC2 cells purified from TDLs
of normal 12-wk-old PVG rats or with 106 CD41CD82
thymocytes purified from thymus of normal 6-wk-old syn-
geneic donors. Control rats received no cells. Groups of
rats reconstituted with cells were then treated with either
OX81 (2 mg/injection) or 2G.7 (2 mg/injection) mAbs
that specifically block the biological activities of rat IL-4
(19) and rat TGF-b (31) respectively, while other groups
received isotype-matched negative control mAbs at the
same dose. Rats were injected with mAb 1 d before and 1 d
after reconstitution and then twice weekly thereafter for 4 wk.
This length of treatment was chosen because previous stud-
ies had shown that rats are protected from disease develop-
ment when reconstituted with lymphocytes up to 14 d af-
ter the last irradiation. Development of thyroiditis in rats
reconstituted 4 wk after the last irradiation was unaffected
by the injection of the regulatory T cells (30), suggesting
that these cells have, at most, a 4-wk window after the final
irradiation in which they can affect disease development.
TxX rats reconstituted with a dose of 5 3 106 CD41
CD45RC2 cells and either untreated or treated with iso-
type-matched negative control mAbs were effectively pro-
tected from development of thyroiditis, with only 7 out of
32 rats developing any disease compared with 25 out of 32
controls rats (Fig. 5 A). However, treatment of TxX rats
with mAbs specific for either TGF-b or IL-4 after their re-
constitution with CD41CD45RC2 cells developed thy-
roiditis at a frequency comparable with that of control rats
(Fig. 5 A). 9 out of 13 TxX rats reconstituted with
CD41CD45RC2 cells and treated with anti–TGF-b mAb
developed anti-Tg autoantibody responses, whereas all rats
similarly reconstituted but treated with anti-IL-4 mAb
made anti-Tg IgG. Significantly, although 7 out of 30 rats
reconstituted with 106 CD41CD82 thymocytes were pro-
tected from thyroiditis development (Fig. 5 B), rats simi-
larly reconstituted but treated with anti–TGF-b or anti–IL-4
mAbs developed disease at a frequency similar to that of
controls. Of those TxX rats reconstituted with 106
CD41CD82 thymocytes, 8 out of 10 anti–TGF-b mAb-
treated rats and 12 out of 15 anti–IL-4 mAb-treated rats
developed thyroiditis (Fig. 5 B), compared with an inci-
dence of 16 out of 22 control rats.
Blockade of IL-4 and TGF-b in TxX Rats Reconstituted
with CD41CD45RC2 Cells or CD41CD82 Thymocytes
Does Not Affect the anti-Tg IgG Response. IL-4 has long
been known to play a major role in developmental regula-
tion of Th1 and Th2 immune responses, and in vivo block-
ade of its biological activity during immune responses is
Figure 4. CD41CD82 thymocytes are more potent than CD41
CD45RC2 cells at preventing development of thyroiditis in TxX PVG
rats. PVG rats were thymectomized at 3 wk of age and given four equal
doses of 275-rad 137Cs g-irradiation at 2-wk intervals starting 1 wk after
thymectomy. CD41CD82 thymocytes were purified from thymus of
6-wk-old PVG rats by depletion of CD81 cells, and CD41CD45RC2 cells
were purified from TDLs of 12-wk-old PVG rats by depletion of CD81
and CD45RC1 cells. Shortly after their last irradiation, groups of rats were
reconstituted either with CD41CD82 thymocytes at doses of 105, 5 3 105,
106, 5 3 106, or 107 per rat, or with CD41CD45RC2 cells at doses of 106,
5 3 106, or 107 per rat. Development of anti-Tg antibodies was determined
between 4 and 12 wk after the final irradiation by specific ELISA. Data are
expressed as percentage of rats protected from development of disease,
where the incidence of protection in the control group (42 out of 125 con-
trol rats failed to develop disease) is considered 0% protection. NP, no pro-
tection. Statistics versus controls: aP . 0.11; bP , 0.0046; cP , 1.6 3 1027;
dP , 2.3 3 1026; eP , 1.8 3 1025; fP . 0.4; gP , 8 3 1029; hP , 7 3
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therefore likely to affect the balance of Th1/Th2 T cell de-
velopment. Therefore, it was possible that treatment of
TxX rats with cytokine-blocking mAbs was altering the
development of disease and consequent involvement of
Th1/Th2 T cell subsets to a response type that neither
CD41CD45RC2 cells nor CD41CD82 thymocytes could
regulate. To examine this possibility, the IgG isotype of
anti-Tg responses in reconstituted TxX rats treated with
anti–IL-4 mAb or anti–TGF-b mAb was assessed to deter-
mine whether there had been a change in the relative ac-
tivity of Th2 and Th1 cells in these rats. As the data show,
the IgG isotypes in anti-Tg responses of rats reconstituted
with either CD41CD45RC2 cells or CD41CD82 thy-
mocytes and treated with either anti–IL-4 or anti–TGF-b
mAbs were the same as those of controls (Fig. 6). Anti-Tg
responses of anti-cytokine-treated rats were predominantly
of the Th2-associated IgG1 isotype, with little or no IgG2b
anti-Tg detectable. Therefore, these data support the view
that blockade of either IL-4 or TGF-b with neutralizing
mAbs in TxX rats reconstituted with CD41CD45RC2 T
cells or those given CD41CD82 thymocytes abrogates the
protection mediated by these populations with no modula-
tion of the disease process itself.
Discussion
There are close similarities between the autoimmune thy-
roiditis reported here and the insulin-dependent diabetes
described in earlier papers from this laboratory. In both cases
a tissue-specific autoimmune disease develops after experi-
mentally induced lymphopenia, and the disease can be pre-
vented by the injection of peripheral CD41CD45RC2 T
cells or CD41CD82 thymocytes from normal syngeneic
donors (reference 9 and Fig. 2). However, there are signifi-
cant differences that are informative in determining the
mode of action of the regulatory T cells that prevent these
diseases.
Figure 5. Treatment of TxX rats with neutralizing mAbs against TGF-b
or IL-4 abrogates protection from thyroiditis by both CD41CD45RC2
cells and CD41CD82 thymocytes. Shortly after their last irradiation,
groups of TxX PVG rats were injected with either 5 3 106
CD41CD45RC2 cells purified from TDLs of 12-wk-old normal PVG
rats or 106 CD41CD82 thymocytes purified from thymus of 6-wk-old
normal PVG rats. Control rats received no cells. Rats reconstituted with
cells were treated the day before and the day after cell transfer and then
twice weekly for 4 wk with either the anti–TGF-b–neutralizing mAb
2G.7 (mouse IgG2a; 2 mg/injection) or the anti–IL-4–neutralizing mAb
OX81 (mouse IgG1; 2 mg/injection). Control rats reconstituted with
cells either received no further treatment or were injected with one of the
isotype-control mAbs OX21 (mouse IgG1; 2 mg/injection) or W6/32
(mouse IgG2a; 2 mg/injection) specific for human determinants. Data
represent peak anti-Tg antibody levels of individual TxX rats reconsti-
tuted with either CD41CD45RC2 cells (A) or CD41CD82 thymocytes
(B). Anti-Tg titers are expressed as percentage of standard and data are the
pool of five independent experiments. Statistics versus controls: aP , 2.5
3 1024; bP , 3.1 3 1024; cP . 0.39; dP . 0.07; eP , 0.0021; fP ,
0.008; gP . 0.51; hP . 0.46; versus reconstituted rats treated with control
mAb (b and f): cP , 0.016; dP , 2 3 1025; gP , 0.013; hP , 0.005.
Figure 6. IgG isotypes of anti-Tg antibodies in TxX rats is not affected
by their treatment with anti–IL-4 or anti–TGF-b blocking mAbs. The
relative isotype usage of anti-Tg IgG responses was determined for TxX
rats reconstituted with CD41CD45RC2 cells but treated with either
anti–IL-4 (n 5 9) or anti–TGF-b (n 5 7) blocking mAbs and those
reconstituted with CD41CD82 thymocytes and treated with either anti-
IL-4 (n 5 6) or anti-TGF-b (n 5 9) blocking mAbs from the experi-
ments described in Fig. 5. The isotype of anti-Tg IgG in sera of control
rats (n 5 16) from both these series of experiments was similarly deter-
mined by specific ELISA. Data are expressed as the mean percentage of
the anti-Tg response for a given IgG isotype where 100% is the sum of
the ODs for individual isotypes above background of normal PVG sera in
1:10 dilutions of an experimental serum. Error bars indicate SD.285 Seddon and Mason
The diabetes that develops in lymphopenic PVG.RT1u
rats has the features of a cell-mediated disease in which
CD81 T cells play an essential role. In contrast, the au-
toimmune thyroiditis in TxX PVG rats, described in this
paper, is characterized by a strong humoral component.
CD81 T cells are not required for the development of this
disease (Fig. 1 B) and the anti-Tg IgG antibodies that de-
velop are predominantly of the IgG1 isotype (Fig. 1 A). In
principle, this observation could be explained if PVG rats
are able to make only a Th2-type immune response to Tg.
However, active immunization of PVG rats with Tg/CFA
induces anti-Tg antibodies that are mainly IgG2b rather
than IgG1 (Fig. 1 A) demonstrating that PVG rats, when
appropriately challenged, are able to make an anti-Tg anti-
body response characteristic of Th1 activity. Despite the
fact that the diabetes and thyroiditis that develop in TxX
rats have characteristics of Th1 and Th2 autoimmune re-
sponses respectively, the same CD41CD45RC2 subset of
peripheral T cells was able to completely prevent both dis-
eases (Fig. 2 and reference 6). This observation counters
the suggestion that regulatory T cells prevent diabetes in
TxX PVG.RT1u rats by inducing a Th1 to Th2 switch in
the autoimmune response. Similarly, the suppression of au-
toantibody synthesis in the TxX PVG rats by the transfer of
CD41CD45RC2 T cells is incompatible with such a
change in T cell function since the anti-Tg autoantibody in
unprotected rats already has the characteristics of a Th2 re-
sponse. Taken together, the data from the two autoim-
mune diseases do not support the proposal that the control
of autoimmunity involves a change in the balance between
Th1 and Th2 responses to an autoantigen (32, 33). Instead,
the regulatory T cells that prevent organ-specific autoim-
mune diseases appear to suppress autoimmune T cells com-
pletely. A recent publication draws the same conclusion
(34).
The experiments on the relative potency of peripheral
CD41CD45RC2 T cells and CD41CD82 thymocytes in
controlling thyroiditis in TxX PVG rats indicated that the
latter cells were effective at one-tenth the dose of the
peripheral ones (Fig. 4), a result that closely resembles
the findings on the control of autoimmune diabetes in
PVG.RT1u rats (9). The experiments on the mode of ac-
tion of these regulatory cells in preventing thyroiditis indi-
cated that both IL-4 and TGF-b are involved in this mech-
anism (Figs. 5 and 6), and this was true whether peripheral
T cells or thymocytes were used to control the disease.
This result suggests that the differences in the numbers of
protective cells from these two sources, required to control
autoimmunity in TxX rats, cannot be explained in terms of
differences in the way in which they mediated protection.
This conclusion is relevant when considering the nature of
the homeostatic mechanism that controls the size of the
regulatory T cell population. When CD41CD82 thy-
mocytes were used to prevent these diseases, they were
injected into recipients that were highly deficient in reg-
ulatory T cells. Consequently, a homeostatic control mech-
anism would be expected to permit a relatively large num-
ber of thymocyte precursors to differentiate into cells with
regulatory function. In contrast, there is evidence (see be-
low) that the mature peripheral CD41CD45RC2 regula-
tory T cells, which were obtained from normal, healthy
donors, represent a population whose frequency has been
subject to homeostatic control within these nonlym-
phopenic animals. It appears that few extra regulatory T cells
(T reg) can be recruited from the peripheral T cell pool
when donor CD41 T cells are transferred into TxX recipi-
ents. Consequently, peripheral T cells are a less potent
source of T reg than are thymocytes that have not been ex-
posed to the homeostatic mechanism that determines the
size of the peripheral T reg population.
The intrinsic nature of the homeostatic mechanism is not
directly addressed by these experiments but the data are
best explained by a process in which the number of thy-
mocytes that develop into peripheral regulatory T cells is
determined by the requirement that this number should be
just adequate to control the potentially autoreactive T cells
that are part of the normal T cell repertoire (6). As with the
previous observations on the control of diabetes in TxX
rats (9), the data in Fig. 4 show that the percentage of rats
protected from autoimmunity by CD41CD82 thymocytes
is very insensitive to the dose of thymocytes used and that
the majority of, but not all, rats are protected from thy-
roiditis by unfractionated CD41 peripheral T cells. In the
experiments on diabetes in TxX rats, we proposed that
these findings indicated that there is a delicate balance be-
tween the number of autoreactive T cells in the periphery
and the number of T reg that control them, with the latter
population being in a slight functional excess. This inter-
pretation was supported by the close agreement between
the experimental findings and a mathematical model based
on this concept (9). The data presented here on autoim-
mune thyroiditis are also compatible with this interpreta-
tion. The most economical explanation of how this balance
between the two populations of T cells is achieved is that
exposure of regulatory T cell precursors and potentially au-
toreactive T cells to the specific autoantigen leads to an in-
teraction between them and that this interaction ceases
only after the regulatory T cells so generated are sufficient
to control the autoreactive T cells. This hypothesis would
require the presence of the relevant autoantigen in the pe-
riphery to transiently stimulate the autoreactive T cells.
Consistent with this proposed mechanism, we have re-
cently shown that peripheral regulatory T cells that prevent
thyroiditis are not found in rats whose thyroids have been
ablated by 131I treatment in utero (Seddon, B., and D. Ma-
son, manuscript submitted for publication). In summary,
the data indicate that the mature CD41CD82 thymocyte
population contains a high frequency of cells that have the
potential to differentiate in the periphery into regulatory T
cells that prevent organ-specific autoimmunity. In normal
animals this differentiation is homeostatically controlled,
such that the number of regulatory T cells generated is just
sufficient to prevent disease. The generation of regulatory
T cells in the periphery from thymic migrants does not take
place in the absence of the target autoantigen, so the nu-
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cells is not established. Under such circumstances, the en-
graftment of the relevant organ leads to its rejection (35).
The immunosuppressive effect of TGF-b has been re-
ported in a number of systems (36–40) and has been impli-
cated in suppression of both cell-mediated responses, as in
models of inflammatory bowel disease (41) and humoral
autoimmunity induced by mercuric chloride (31). Conse-
quently, the essential role that it plays in the prevention of
autoimmune thyroiditis in TxX rats is not unexpected. As
TGF-b prevents T cell activation but does not kill acti-
vated cells, it appears that T reg suppress but do not elimi-
nate autoreactive T cells. This conclusion is compatible
with the observation that such autoreactive cells form part
of the normal T cell repertoire, but it raises the question of
the value of a mechanism that preserves self-tolerance but
also preserves the autoreactive cells. As discussed elsewhere
(42), the establishment of self-tolerance by a mechanism
that irreversibly silences all potentially autoreactive T cells
would virtually completely deplete the T cell repertoire.
The implication seems to be that the maintenance of self-
tolerance by a dominant regulatory process is required to
preserve a T cell repertoire that can react to essentially all
foreign MHC-binding peptides. If this is so, then T reg
would be required to inhibit autoreactive T cells when
these are stimulated by self-antigens but not by foreign
ones. This distinction may come about because peripheral
autoreactive T cells for self-antigens have low affinity re-
ceptors for self-epitopes since T cells with high affinity re-
ceptors have been intrathymically clonally deleted. It is no-
table in this context that there is compelling evidence for
the intrathymic expression of many “tissue-specific” au-
toantigens, including insulin and Tg (43–45) and that poly-
morphisms in the level of expression influence susceptibil-
ity (46).
A deficiency of IL-4 has been implicated in the patho-
genesis of insulin-dependent diabetes mellitus in the NOD
mouse (33, 47, 48) but this view is not universally accepted
(49). Furthermore, IL-4 plays no essential part in the pre-
vention of inflammatory bowel disease in mice (41), and
regulatory T cells that prevent this condition appear not to
produce this cytokine in vitro (50). In contrast, in our cur-
rent experiments the neutralization of IL-4 by specific anti-
body completely abrogated the protection from autoim-
mune thyroiditis provided by the transfer of syngeneic
CD41 T cells. Although this result would at first appear to
contradict the view that autoimmune thyroiditis is medi-
ated by a humoral Th2 mechanism, it is possible that the
requirement for IL-4 by regulatory and autoreactive T cells
may occur at different times, even if the same anatomical
site is implicated. Support for this comes from the observa-
tion that suppression of disease by reconstitution of rats
with T cells is only successful up to 2 but not 4 wk after the
last irradiation (30), whereas development of anti-Tg anti-
bodies in TxX PVG rats occurs only between 4 and 12 wk
after the last irradiation. Despite this finding, we cannot
conclude with certainty that there was a deficiency of IL-4
in the rats that developed thyroiditis, since a deficiency in
TGF-b would have sufficed to cause the disease. The IgG1
isotype of the anti-Tg antibody in the rats with thyroiditis
is compatible with the presence of IL-4, but this antibody
isotype is not strictly IL-4–dependent (51). Despite these
uncertainties, the experimental data in Figs. 5 and 6 indi-
cate that an anti–IL-4 antibody–induced IL-4 deficiency
does result in the development of autoimmune thyroiditis
in TxX rats.
Relevant to discussions of the possible functional role of
IL-4 in the prevention of autoimmunity, it is significant
that mouse T cells activated in the presence of IL-4 secrete
high levels of TGF-b during both primary and secondary
stimulations (52). This raises the possibility that IL-4 is a
growth factor for regulatory T cells, whereas TGF-b acts as
the effector cytokine in the suppression of autoimmune re-
sponses such that a deficiency of either cytokine will result
in breakdown of regulation. Consequently, these data are
in accord with those studies that implicate a deficiency of
IL-4 in the pathogenesis of insulin-dependent diabetes
mellitus in NOD mice and suggest that it plays an impor-
tant role in the prevention of organ-specific autoimmune
diseases. The failure to show a similar involvement of this
cytokine in the prevention of inflammatory bowel disease
indicates that regulatory T cells do not necessarily form a
functionally homogeneous population.
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